<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rmt</journal-id><journal-title-group><journal-title xml:lang="ru">Общая реаниматология</journal-title><trans-title-group xml:lang="en"><trans-title>General Reanimatology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1813-9779</issn><issn pub-type="epub">2411-7110</issn><publisher><publisher-name>FSBI "SRIGR" RAMS</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15360/1813-9779-2025-3-2563</article-id><article-id custom-type="elpub" pub-id-type="custom">rmt-2594</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EXPERIMENTAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Влияние ксенона на содержание ГСК-3β, NF-κB и Nrf2 в головном мозге крыс (экспериментальное исследование)</article-title><trans-title-group xml:lang="en"><trans-title>The Effects of Xenon on GSK-3β, NF-κB, and Nrf2 Levels in the Rat Brain: An Experimental Study</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-4637-7598</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Беда</surname><given-names>Е. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Beda</surname><given-names>E. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Евгений Евгеньевич Беда</p><p>10703, г. Москва, ул. Петровка, д. 25, стр. 2</p></bio><bio xml:lang="en"><p>Evgeniy E. Beda</p><p>25 Petrovka Str., Bldg. 2, 107031 Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-9615-6118</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Габитов</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Gabitov</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Михаил Валерьевич Габитов</p><p>10703, г. Москва, ул. Петровка, д. 25, стр. 2</p></bio><bio xml:lang="en"><p>Mikhail V. Gabitov</p><p>25 Petrovka Str., Bldg. 2, 107031 Moscow</p></bio><email xlink:type="simple">gabitovmv@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7008-2038</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Редкин</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Redkin</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Иван Валерьевич Редкин</p><p>10703, г. Москва, ул. Петровка, д. 25, стр. 2</p></bio><bio xml:lang="en"><p>Ivan V. Redkin</p><p>25 Petrovka Str., Bldg. 2, 107031 Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3121-2981</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Крюков</surname><given-names>И.  А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kryukov</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Иван Александрович Крюков</p><p>10703, г. Москва, ул. Петровка, д. 25, стр. 2</p></bio><bio xml:lang="en"><p>Ivan A. Kryukov</p><p>25 Petrovka Str., Bldg. 2, 107031 Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9045-6017</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гребенчиков</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Grebenchikov</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Олег Александрович Гребенчиков</p><p>10703, г. Москва, ул. Петровка, д. 25, стр. 2</p></bio><bio xml:lang="en"><p>Oleg A. Grebenchikov</p><p>25 Petrovka Str., Bldg. 2, 107031 Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>НИИ общей реаниматологии им. В. А. Неговского, Федеральный научно-клинический центр реаниматологии и реабилитологии</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V. A. Negovsky Research Institute of General Reanimatology, Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>25</day><month>06</month><year>2025</year></pub-date><volume>21</volume><issue>3</issue><fpage>26</fpage><lpage>31</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Беда Е.Е., Габитов М.В., Редкин И.В., Крюков И.А., Гребенчиков О.А., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Беда Е.Е., Габитов М.В., Редкин И.В., Крюков И.А., Гребенчиков О.А.</copyright-holder><copyright-holder xml:lang="en">Beda E.E., Gabitov M.V., Redkin I.V., Kryukov I.A., Grebenchikov O.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.reanimatology.com/rmt/article/view/2594">https://www.reanimatology.com/rmt/article/view/2594</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования. Изучение влияния субанестетических концентраций ксенона на содержание ГСК-3β, NF-κB и Nrf2 в головном мозге интактных крыс.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Лабораторных животных разделили на группы: 1-я группа Контроль — ингаляция азот-кислородной смеси, n=5; 2-я группа Xe-70 — ингаляция ксенона в концентрации 70%, n=5; 3-я группа Xe-35 — ингаляция ксенона в концентрации 35%, n=5. После эвтаназии лабораторных крыс выполнили вестерн-блоттинг с последующим денситометрическим анализом тканей мозга на содержание фосфо-ГСК-3β, NF-κB и Nrf2.</p></sec><sec><title>Результаты</title><p>Результаты. Ингаляция ксенон-кислородной смеси привела к статистически значимому увеличению фосфорилированной формы ГСК-3β в группе Xe-70 (95% ДИ: 593723–1018826; p=0,0001; r=0,72) и Xe-35 (95% ДИ: 872807–458413; p=0,0001; r=0,80) по отношению к группе Контроль. Применение ксенона привело к значимому снижению количества NF-κB в группе Xe-70 (95% ДИ: 205138–601617; p=0,0005; r=0,95) и Xe-35 (95% ДИ: 217700–608462; p=0,0003; r=0,95) по отношению к группе Контроль. Ингаляция ксенона привела к статистически значимому увеличению содержания белка Nrf2 в группе Xe-35 по отношению к группе Контроль (95% ДИ: 692532–260926; p=0,0002; r=0,91).</p></sec><sec><title>Заключение</title><p>Заключение. Ксенон в субанестетических концентрациях значимо влияет на содержание ГСК-3β, NF-kB и Nrf2 в головном мозге интактных крыс.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To evaluate the impact of subanesthetic concentrations of xenon on the brain levels of GSK-3β, NF-κB, and Nrf2 in intact rats.</p></sec><sec><title>Materials and Methods</title><p>Materials and Methods. Male laboratory rats were randomly assigned to three groups (N=5 per group): the control group received inhalation of a nitrogen-oxygen gas mixture; the Xe-70 group received 70% xenon; and the Xe-35 group received 35% xenon. Following euthanasia, brain tissue samples were analyzed using Western blotting and densitometric quantification to assess levels of phosphorylated GSK-3β, NF-κB, and Nrf2. Results. Inhalation of xenon-oxygen mixtures led to a statistically significant increase in phosphorylated GSK-3β levels in both the Xe-70 group (95% CI: 593,723–1,018,826; P=0.0001; R=0.72) and the Xe-35 group (95% CI: 458,413–872,807; P=0.0001; R=0.80), compared with controls. Xenon exposure also resulted in a significant reduction in NF-κB levels in the Xe-70 (95% CI: 205,138–601,617; P=0.0005; R=0.95) and Xe-35 (95% CI: 217,700–608,462; P=0.0003; R=0.95) groups. Furthermore, Nrf2 protein expression was significantly elevated in the Xe-35 group compared to controls (95% CI: 260,926–692,532; P=0.0002; R=0.91).</p></sec><sec><title>Conclusion</title><p>Conclusion. Subanesthetic xenon concentrations exert a significant modulatory effect on GSK-3β, NF-κB, and Nrf2 expression in the brain tissue of intact rats.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ксенон</kwd><kwd>ГСК-3β</kwd><kwd>NF-κB</kwd><kwd>Nrf2</kwd><kwd>головной мозг</kwd><kwd>крысы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>xenon</kwd><kwd>GSK-3β</kwd><kwd>NF-κB</kwd><kwd>Nrf2</kwd><kwd>brain</kwd><kwd>rats</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Mousavikia S. N., Darvish L., Firouzjaei A. A., Toossi M. T. B., Azimian H. J. PI3K/AKT/mTOR targeting in colorectal cancer radiotherapy: a systematic review. Gastrointest Cancer. 2025; 56 (1): 52. DOI: 10.1007/s12029-024-01160-1. PMID: 39849185.</mixed-citation><mixed-citation xml:lang="en">Mousavikia  S.  N., Darvish L., Firouzjaei  A.  A., Toossi  M.  T.  B., Azimian  H.  J. PI3K/AKT/mTOR targeting in colorectal cancer radiotherapy: a systematic review. Gastrointest Cancer. 2025; 56 (1): 52. DOI: 10.1007/s12029-024-01160-1. PMID: 39849185.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Park J. I. MAPK-ERK pathway. Int J Mol Sci. 2023; 24 (11): 9666. DOI: 10.3390/ijms24119666. PMID: 37298618.</mixed-citation><mixed-citation xml:lang="en">Park  J.  I. MAPK-ERK pathway. Int J Mol Sci. 2023; 24 (11): 9666. DOI: 10.3390/ijms24119666. PMID: 37298618.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Iluta S., Nistor M., Buruiana S., Dima D. Wnt signaling pathway in tumor biology. Genes (Basel). 2024; 15 (12): 1597. DOI: 10.3390/genes15121597. PMID: 39766864.</mixed-citation><mixed-citation xml:lang="en">Iluta S., Nistor M., Buruiana S., Dima D. Wnt signaling pathway in tumor biology. Genes (Basel). 2024; 15 (12): 1597. DOI: 10.3390/genes15121597. PMID: 39766864.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Hu Q., Bian Q., Rong D., Wang L., Song J., Huang H. S., Zeng J., et al. JAK/STAT pathway: extracellular signals, diseases, immunity, and therapeutic regimens. Front Bioeng Biotechnol. 2023; 11: 1110765. DOI: 10.3389/fbioe.2023.1110765. eCollection 2023. PMID: 36911202.</mixed-citation><mixed-citation xml:lang="en">Hu Q., Bian Q., Rong D., Wang L., Song J., Huang H. S., Zeng J., et al. JAK/STAT pathway: extracellular signals, diseases, immunity, and therapeutic regimens. Front Bioeng Biotechnol. 2023; 11: 1110765. DOI: 10.3389/fbioe.2023.1110765. eCollection 2023. PMID: 36911202.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Острова И. В., Гребенчиков О. А., Голубева Н. В. Нейропротективное действие хлорида лития на модели остановки сердца у крыс. Общая реаниматология. 2019; 15 (3): 73–82.</mixed-citation><mixed-citation xml:lang="en">Ostrova I. V., Grebenchikov O. A., Golubeva N. V. Neuroprotective effect of lithium chloride in rat model of cardiac arrest. General Reanimatology= Obshchaya Reanimatologiya. 2019; 15 (3): 73–82. (in Russ.&amp;Eng.). DOI: 10.15360/1813-9779-2019-3-73-82.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang J., Yang S. G., Zhou F. Q. Glycogen synthase kinase 3 signaling in neural regeneration in vivo. J Mol Cell Biol. 2024; 15 (12): mjad075. DOI: 10.1093/jmcb/mjad075. PMID: 38059848.</mixed-citation><mixed-citation xml:lang="en">Zhang J., Yang S. G., Zhou F. Q. Glycogen synthase kinase 3 signaling in neural regeneration in vivo. J Mol Cell Biol. 2024; 15 (12): mjad075. DOI: 10.1093/jmcb/mjad075. PMID: 38059848.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Saha S., Buttari B., Panieri E., Profumo E., Saso L. An overview of Nrf2 signaling pathway and its role in inflammation. Molecules. 2020; 25 (22): 5474. DOI: 10.3390/molecules25225474. PMID: 33238435.</mixed-citation><mixed-citation xml:lang="en">Saha S., Buttari B., Panieri E., Profumo E., Saso L. An overview of Nrf2 signaling pathway and its role in inflammation. Molecules. 2020; 25 (22): 5474. DOI: 10.3390/molecules25225474. PMID: 33238435.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Шиловский Г. А., Сорокина Е. В., Орловский И. В. Транскрипционный фактор NRF2 — мишень активирующих антиоксидантную систему клетки препаратов: перспективы применения при возрастных заболеваниях. Клиническая геронтология. 2021; 27 (11–12): 57–62.</mixed-citation><mixed-citation xml:lang="en">Shilovsky G. A., Sorokina E. V., Orlovsky I. V. Transcription factor NRF2 — a target of potential antioxidant drugs: prospects in treatment of age–related diseases. Clinical Gerontology= Klinicheskaya Gerontologiya. 2021; 27 (11–12): 57–62. (in Russ.). DOI: 10.26347/1607-2499202111-12057-062.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Barnabei L., Laplantine E., Mbongo W., Rieux-Laucat F., Weil R. NF-kappaB: at the borders of autoimmunity and inflammation. Front Immunol. 2021; 12: 716469. DOI: 10.3389/fimmu.2021.716469. PMID: 34434197</mixed-citation><mixed-citation xml:lang="en">Barnabei L., Laplantine E., Mbongo W., Rieux-Laucat F., Weil R. NF-kappaB: at the borders of autoimmunity and inflammation. Front Immunol. 2021; 12: 716469. DOI: 10.3389/fimmu.2021.716469. PMID: 34434197</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Боева Е. А., Гребенчиков О. А. Органопротективные свойств аргона (обзор). Общая реаниматология. 2022; 18 (5): 44–59.</mixed-citation><mixed-citation xml:lang="en">Boeva  E.  A., Grebenchikov  O.  A. Organoprotective properties of argon (review). General Reanimatology = Obshchaya Reanimatologiya. 2022; 18 (5): 44–59. (in Russ.&amp;Eng.). DOI: 10.15360/1813-9779-2022-5-44-59.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kaufman M. J., Meloni E. G. Xenon gas as a potential treatment for opioid use disorder, alcohol use disorder, and related disorders. Med Gas Res. 2025; 15 (2): 234–253. DOI: 10.4103/mgr.MEDGASRES-D-24-00063. PMID: 39812023.</mixed-citation><mixed-citation xml:lang="en">Kaufman M. J., Meloni E. G. Xenon gas as a potential treatment for opioid use disorder, alcohol use disorder, and related disorders. Med Gas Res. 2025; 15 (2): 234–253. DOI: 10.4103/mgr.MEDGASRES-D-24-00063. PMID: 39812023.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Antonova V. V., Silachev D. N., Plotnikov E. Y., Pevzner I. B., Yakupova E. I., Pisarev M. V., Boeva E. A., et al. Neuroprotective effects of krypton inhalation on photothrombotic ischemic stroke. Biomedicines. 2024; 12 (3): 635. DOI: 10.3390/biomedicines12030635. PMID: 38540249.</mixed-citation><mixed-citation xml:lang="en">Antonova  V.  V., Silachev  D.  N., Plotnikov  E.  Y., Pevzner  I.  B., Yakupova  E.  I., Pisarev  M.  V., Boeva  E.  A., et al. Neuroprotective effects of krypton inhalation on photothrombotic ischemic stroke. Biomedicines. 2024; 12 (3): 635. DOI: 10.3390/biomedicines12030635. PMID: 38540249.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Гребенчиков О. А., Молчанов И. В., Шпичко А. И., Евсеев А. К., Шабанов А. К., Хусаинов Ш. Ж., Петриков С. С. Нейропротективные свойства ксенона по данным экспериментальных исследований. Журнал им. Н. В. Склифосовского Неотложная медицинская помощь. 2020; 9 (1): 85–95.</mixed-citation><mixed-citation xml:lang="en">Grebenchikov  O.  A., Molchanov  I.  V., Shpichko  A.  I., Evseev  A.  K., Shabanov  A.  K., Khusainov S. Z., Petrikov S. S. Neuroprotective properties of xenon according to experimental studies. Russian Sklifosovsky Journal «Emergency Medical Care» = Zhurnal im.  N.  V. Sklifosovskogo «Neotlozhnaya Meditsinskaya Pomoshch». 2020; 9 (1): 85–95. (in Russ.). DOI:10.23934/2223-9022-2020-9-l-85-95.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Беда Е. Е., Габитов М. В., Гребенчиков О. А. Влияние ксенона в различных концентрациях на объем поражения головного мозга и выраженность неврологических нарушений у крыс при моделировании открытои черепно-мозговои ̆ травмы. ̆ Патологическая физиология и экспериментальная терапия. 2024; 68 (1): 26-36.</mixed-citation><mixed-citation xml:lang="en">Beda E. E., Gabitov M. V., Grebenchikov O. A. The effect of xenon in various concentrations on the volume of brain damage and severity of neurological disorders in rat model of open traumatic brain injury. Pathological Physiology and Experimental Therapy = Patologicheskaya Fiziologiya i Exsperimentalnaya Terapiya. 2024; 68 (1): 26-36. (in Russ.). DOI: 10.25557/0031-2991.2024.01.26-36.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Шпичко А. И., Гребенчиков О. А., Молчанов И. В., Шабанов А. К., Шпичко Н. П., Каданцева К. К. Кардиопротективные свойства ксенона. Журнал им. Н. В. Склифосовского Неотложная медицинская помощь. 2020; 9 (2): 266–271.</mixed-citation><mixed-citation xml:lang="en">Shpichko  A.  I., Grebenchikov O. A., Molchanov I. V., Shabanov A. K., Shpichko N. P., Kadantseva  K.  K. Cardioprotective properties of xenon. Russian Sklifosovsky Journal «Emergency Medical Care» = Zhurnal im. N. V. Sklifosovskogo «Neotlozhnaya Meditsinskaya Pomoshch». 2020; 9 (2): 266–271. (in Russ.). DOI: 10.23934/2223-9022-2020-9-2-96-107.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Nakata Y., Goto T., Ishiguro Y., Terui K., Kawakami H., Santo M., Niimi Y., et al. Minimum alveolar concentration (MAC) of xenon with sevoflurane in humans. J Am Soc Anesthesiol. 2001; 94 (4): 611–614. DOI: 10.1097/00000542-200104000-00014. PMID: 11379681.</mixed-citation><mixed-citation xml:lang="en">Nakata Y., Goto T., Ishiguro Y., Terui K., Kawakami H., Santo M., Niimi Y., et al. Minimum alveolar concentration (MAC) of xenon with sevoflurane in humans. J Am Soc Anesthesiol. 2001; 94 (4): 611–614. DOI: 10.1097/00000542-200104000-00014. PMID: 11379681.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Cullen S. C., Eger E. D. II, Cullen B. F., Gregory P. Observations on the anesthetic effect of the combination of xenon and halothane. Anesthesiology. 1969; 31: 305-30. DOI: 10.1097/00000542-196910000-00003. PMID: 5811596.</mixed-citation><mixed-citation xml:lang="en">Cullen S. C., Eger E. D. II, Cullen B. F., Gregory P. Observations on the anesthetic effect of the combination of xenon and halothane. Anesthesiology. 1969; 31: 305-30. DOI: 10.1097/00000542-196910000-00003. PMID: 5811596.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Koblin D. D., Fang Z., Eger E. I., Laster M. J., Gong D., Ionescu P., Halsey M. J., et al. Minimum alveolar concentrations of noble gases, nitrogen, and sulfur hexafluoride in rats: helium and neon as nonimmobilizers (nonanesthetics). Anesth Analg. 1998; 87 (2): 419–424. DOI: 10.1213/00000539-199808000-00035. PMID: 9706943.</mixed-citation><mixed-citation xml:lang="en">Koblin D. D., Fang Z., Eger E. I., Laster M. J., Gong D., Ionescu P., Halsey M. J., et al. Minimum alveolar concentrations of noble gases, nitrogen, and sulfur hexafluoride in rats: helium and neon as nonimmobilizers (nonanesthetics). Anesth Analg. 1998; 87 (2): 419–424. DOI: 10.1213/00000539-199808000-00035. PMID: 9706943.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Политов М. Е., Подпругина С. В., Золотова Е. Н., Ногтев П. В., Агакина Ю. С., Жукова С. Г., Яворовский А. Г. Клиническое применение ксенона в субанестетических концентрациях (обзор). Общая реаниматология. 2025; 21 (2): 55–67.</mixed-citation><mixed-citation xml:lang="en">Politov  M.  E., Podprugina  S.  V., Zolotova  E.  N., Nogtev  P.  V., Agakina Yu. S., Zhukova  S.  G., Yavorovsky  A.  G. Clinical application of xenon in subanesthetic concentrations (review). General Reanimatology = Obshchaya Reanimatologiya. 2025; 21 (2): 55–67. (in Russ&amp;Eng.). DOI: 10.15360/1813-9779-2025-2-2554.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Veldeman M., Coburn M., Rossaint R., Clusmann H., Nolte K., Kremer B., Höllig A. Xenon reduces neuronal hippocampal damage and alters the pattern of microglial activation after experimental subarachnoid hemorrhage: a randomized controlled animal trial. Front Neurol. 2017; 8: 511. DOI: 10.3389/fneur.2017.00511. PMID: 29021779.</mixed-citation><mixed-citation xml:lang="en">Veldeman M., Coburn M., Rossaint R., Clusmann H., Nolte K., Kremer B., Höllig A. Xenon reduces neuronal hippocampal damage and alters the pattern of microglial activation after experimental subarachnoid hemorrhage: a randomized controlled animal trial. Front Neurol. 2017; 8: 511. DOI: 10.3389/fneur.2017.00511. PMID: 29021779.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Amer A. R., Oorschot D. E. Xenon combined with hypothermia in perinatal hypoxic-ischemic encephalopathy: a noble gas, a noble mission. Pediatr Neurol. 2018; 84: 5–10. DOI: 10.1016/j.pediatrneurol.2018.02.009. PMID: 29887039.</mixed-citation><mixed-citation xml:lang="en">Amer A. R., Oorschot D. E. Xenon combined with hypothermia in perinatal hypoxic-ischemic encephalopathy: a noble gas, a noble mission. Pediatr Neurol. 2018; 84: 5–10. DOI: 10.1016/j.pediatrneurol.2018.02.009. PMID: 29887039.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Campos-Pires R., Onggradito H., Ujvari E., Karimi S., Valeo F., Aldhoun J., Edge C. J., et al. Xenon treatment after severe traumatic brain injury improves locomotor outcome, reduces acute neuronal loss and enhances early beneficial neuroinflammation: a randomized, blinded, controlled animal study. Crit Care. 2020; 24: 667. DOI: 10.1186/s13054-020-03373-9. PMID: 33246487.</mixed-citation><mixed-citation xml:lang="en">Campos-Pires R., Onggradito H., Ujvari E., Karimi S., Valeo F., Aldhoun J., Edge C. J., et al. Xenon treatment after severe traumatic brain injury improves locomotor outcome, reduces acute neuronal loss and enhances early beneficial neuroinflammation: a randomized, blinded, controlled animal study. Crit Care. 2020; 24: 667. DOI: 10.1186/s13054-020-03373-9. PMID: 33246487.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Hollmén C., Parkkola R., Vorobyev V., Saunavaara J., Laitio R., Arola O., Hynninen M., et al. Neuroprotective effects of inhaled xenon gas on brain structural gray matter changes after out-ofhospital cardiac arrest evaluated by morphometric analysis: a substudy of the randomized xe-hypotheca trial. Neurocrit Care. 2025; 42 (1): 131–141. DOI: 10.1007/s12028-024-02053-8. PMID: 38982000.</mixed-citation><mixed-citation xml:lang="en">Hollmén C., Parkkola R., Vorobyev V., Saunavaara J., Laitio R., Arola O., Hynninen M., et al. Neuroprotective effects of inhaled xenon gas on brain structural gray matter changes after out-ofhospital cardiac arrest evaluated by morphometric analysis: a substudy of the randomized xe-hypotheca trial. Neurocrit Care. 2025; 42 (1): 131–141. DOI: 10.1007/s12028-024-02053-8. PMID: 38982000.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Brandao W., Jain N., Yin Z., Kleemann K. L., Carpenter M., Bao X., Serrano J. R., et al. Inhaled xenon modulates microglia and ameliorates disease in mouse models of amyloidosis and tauopathy. Sci Transl. Med. 2025; 17 (781): eadk3690. DOI: 10.1126/scitranslmed.adk3690. PMID: 39813317.</mixed-citation><mixed-citation xml:lang="en">Brandao W., Jain N., Yin Z., Kleemann K. L., Carpenter M., Bao X., Serrano  J.  R., et al. Inhaled xenon modulates microglia and ameliorates disease in mouse models of amyloidosis and tauopathy. Sci Transl. Med. 2025; 17 (781): eadk3690. DOI: 10.1126/scitranslmed.adk3690. PMID: 39813317.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Filev A. D., Silachev D. N., Ryzhkov I. A., Lapin K. N., Babkina A. S., Grebenchikov O. A., Pisarev V. M. Effect of xenon treatment on gene expression in brain tissue after traumatic brain injury in rats. Brain Sci. 2021; 11 (7): 889. DOI: 10.3390/brainsci11070889. PMID: 34356124.</mixed-citation><mixed-citation xml:lang="en">Filev A. D., Silachev D. N., Ryzhkov I. A., Lapin K. N., Babkina A. S., Grebenchikov  O.  A., Pisarev  V.  M. Effect of xenon treatment on gene expression in brain tissue after traumatic brain injury in rats. Brain Sci. 2021; 11 (7): 889. DOI: 10.3390/brainsci11070889. PMID: 34356124.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Кабиольский И. А., Симоненко С. Д., Сарычева Н. Ю., Дубынин В. А. Терапевтические эффекты инертных газов. Российский физиологический журнал им. И. М. Сеченова. 2024; 110 (10): 1582–1601.</mixed-citation><mixed-citation xml:lang="en">Kabiolsky  I.  A., Simonenko  S.  D., Sarycheva N.Yu., Dubynin V. A. Therapeutic effects of inert gases. I. M. Sechenov Russian Journal of Physiology = Ross. Fiziol. Zh. Im. I. M. Sechenova. 2024; 110 (10): 1582–1601. (in Russ.). DOI: 10.31857/S0869813924100033.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Гребенчиков O. A., Aврущенко М. Ш., Борисов К. Ю., Ильин Ю. В., Лихванцев В. В. Нейропротекторные эффекты севофлурана на модели тотальной ишемии-реперфузии. Клиническая патофизиология. 2014; 2: 57–62.</mixed-citation><mixed-citation xml:lang="en">Grebenchikov  O.  A., Avrushchenko M. Sh., Borisov K.Yu., Ilyin Yu.V., Likhvantsev V. V. Neuroprotective effects of sevoflurane on a total ischemia-reperfusion model. Clinical Pathophysiology / Klinicheskaya Patofysiologiya. (in Russ.). 2014; 2: 57–62.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Ruiz S. A., Rippin I., Eldar-Finkelman H. Prospects in GSK-3 signaling: from cellular regulation to disease therapy. Cells. 2022; 11 (10): 1618. DOI: 10.3390/cells11101618. PMID: 35626655.</mixed-citation><mixed-citation xml:lang="en">Ruiz  S.  A., Rippin I., Eldar-Finkelman H. Prospects in GSK-3 signaling: from cellular regulation to disease therapy. Cells. 2022; 11 (10): 1618. DOI: 10.3390/cells11101618. PMID: 35626655.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Ершов А. В., Крюков И. А., Антонова В. В., Баева А. А. Влияние ксенона на активность гликоген-синтазы киназы-3β в перифокальной зоне ишемического инсульта (экспериментальное исследование). Общая реаниматология. 2023; 19 (2): 60–67.</mixed-citation><mixed-citation xml:lang="en">Ershov A. V., Krukov I. A., Antonova V. V., Baeva A. A. The effect of xenon on the activity of glycogen synthase kinase-3b in the perifocal zone of ischemic cerebral infarction (experimental study). General Reanimatology = Obshchaya Reanimatologiya. 2023; 19 (2): 60–67. (in Russ.&amp;Eng.). DOI: 10.15360/1813-9779-2023-2-2274.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y., Chu L, Liu C., Zha Z., Shu Y. Protective effect of GSK-3β/Nrf2 mediated by dimethyl fumarate in middle cerebral artery embolization reperfusion rat model. Curr Neurovasc Res. 2021; 18 (4): 456–464. DOI: 10.2174/1567202618666211109105024. PMID: 34751118.</mixed-citation><mixed-citation xml:lang="en">Li Y., Chu L, Liu C., Zha Z., Shu Y. Protective effect of GSK-3β/Nrf2 mediated by dimethyl fumarate in middle cerebral artery embolization reperfusion rat model. Curr Neurovasc Res. 2021; 18 (4): 456–464. DOI: 10.2174/1567202618666211109105024. PMID: 34751118.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Niu Q., Sun W., Chen Q., Long Y., Cao W., Wen S., Li A., et al. Protective effects of ischemic postconditioning on livers in rats with limb ischemia-reperfusion via glycogen synthase kinase 3 beta (GSK-3β)/fyn/nuclear receptor-erythroid-2-related factor (Nrf2) pathway. Med Sci Monit. 2020; 26. DOI: 10.12659/MSM.923049. PMID: 32686659.</mixed-citation><mixed-citation xml:lang="en">Niu Q., Sun W., Chen Q., Long Y., Cao W., Wen S., Li A., et al. Protective effects of ischemic postconditioning on livers in rats with limb ischemia-reperfusion via glycogen synthase kinase 3 beta (GSK-3β)/fyn/nuclear receptor-erythroid-2-related factor (Nrf2) pathway. Med Sci Monit. 2020; 26. DOI: 10.12659/MSM.923049. PMID: 32686659.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Yu H., Lin L., Zhang Z., Zhang H., Hu H. Targeting NF-kappaB pathway for the therapy of diseases: mechanism and clinical study. Signal Transduct Target Ther. 2020; 5 (1): 209. DOI: 10.1038/s41392-020-00312-6. PMID: 32958760.</mixed-citation><mixed-citation xml:lang="en">Yu H., Lin L., Zhang Z., Zhang H., Hu H. Targeting NF-kappaB pathway for the therapy of diseases: mechanism and clinical study. Signal Transduct Target Ther. 2020; 5 (1): 209. DOI: 10.1038/s41392-020-00312-6. PMID: 32958760.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Yang S. R., Hua K. F., Chu L. J., Hwu Y. K., Yang S. M., Wu C. Y., Lin T. J., et al. Xenon blunts NF-kappaB/NLRP3 inflammasome activation and improves acute onset of accelerated and severe lupus nephritis in mice. Kidney Int. 2020; 98 (2): 378–390. DOI: 10.1016/j.kint.2020.02.033. PMID: 32622527.</mixed-citation><mixed-citation xml:lang="en">Yang  S.  R., Hua  K.  F., Chu  L.  J., Hwu  Y.  K., Yang  S.  M., Wu  C.  Y., Lin T. J., et al. Xenon blunts NF-kappaB/NLRP3 inflammasome activation and improves acute onset of accelerated and severe lupus nephritis in mice. Kidney Int. 2020; 98 (2): 378–390. DOI: 10.1016/j.kint.2020.02.033. PMID: 32622527.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao H., Huang H., Ologunde R., Lloyd D. G., Watts H., Vizcaychipi M. P., Lian Q., et al. Xenon treatment protects against remote lung injury after kidney transplantation in rats. Anesthesiology. 2015; 122: 1312–26. DOI: 10.1097/ALN.0000000000000664. PMID: 25856291.</mixed-citation><mixed-citation xml:lang="en">Zhao H., Huang H., Ologunde R., Lloyd  D.  G., Watts H., Vizcaychipi M. P., Lian Q., et al. Xenon treatment protects against remote lung injury after kidney transplantation in rats. Anesthesiology. 2015; 122: 1312–26. DOI: 10.1097/ALN.0000000000000664. PMID: 25856291.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
